300 related articles for article (PubMed ID: 28935493)
41. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL
Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172
[TBL] [Abstract][Full Text] [Related]
42. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
[TBL] [Abstract][Full Text] [Related]
43. [Analysis of the Relationship Between the Quality of Small Biopsy Specimens of
Non-small Cell Lung Cancer and the Mutation Rate of EGFR Gene].
Li Y; Gu Y; Jiang J
Zhongguo Fei Ai Za Zhi; 2021 May; 24(5):331-337. PubMed ID: 34034456
[TBL] [Abstract][Full Text] [Related]
44. A liquid biopsy in primary lung cancer.
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
Surg Today; 2019 Jan; 49(1):1-14. PubMed ID: 29644440
[TBL] [Abstract][Full Text] [Related]
45. EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.
Ju L; Han M; Zhao C; Li X
Lung Cancer; 2016 May; 95():94-7. PubMed ID: 27040858
[TBL] [Abstract][Full Text] [Related]
46. Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs.
Lynch JA; Berse B; Chun D; Rivera D; Filipski KK; Kulich S; Viernes B; DuVall SL; Kelley MJ
Clin Lung Cancer; 2017 Jul; 18(4):401-409. PubMed ID: 28038980
[TBL] [Abstract][Full Text] [Related]
47. Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation.
Russo A; Scilla KA; Mehra R; Gittens A; McCusker MG; de Miguel-Perez D; Gomez JE; Peleg A; Del Re M; Rolfo CD
Clin Lung Cancer; 2023 Nov; 24(7):660-665. PubMed ID: 37487787
[No Abstract] [Full Text] [Related]
48. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
49. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
[TBL] [Abstract][Full Text] [Related]
50. Reliability of EGFR and KRAS mutation analysis on fine-needle aspiration washing in non-small cell lung cancer.
Bozzetti C; Naldi N; Nizzoli R; Azzoni C; Bortesi B; Zobbi V; Bottarelli L; Tiseo M; Gasparro D; Majori M; De Filippo M; Ardizzoni A
Lung Cancer; 2013 Apr; 80(1):35-8. PubMed ID: 23352033
[TBL] [Abstract][Full Text] [Related]
51. Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC.
Van Der Steen N; Mentens Y; Ramael M; Leon LG; Germonpré P; Ferri J; Gandara DR; Giovannetti E; Peters GJ; Pauwels P; Rolfo C
Clin Lung Cancer; 2018 Jan; 19(1):35-41. PubMed ID: 28757336
[TBL] [Abstract][Full Text] [Related]
52. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
[TBL] [Abstract][Full Text] [Related]
53. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
Malapelle U; Sirera R; Jantus-Lewintre E; Reclusa P; Calabuig-Fariñas S; Blasco A; Pisapia P; Rolfo C; Camps C
Expert Rev Mol Diagn; 2017 Mar; 17(3):209-215. PubMed ID: 28129709
[TBL] [Abstract][Full Text] [Related]
54. Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.
Lee DH
Pharmacol Ther; 2017 Jun; 174():1-21. PubMed ID: 28167215
[TBL] [Abstract][Full Text] [Related]
55. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
56. Detection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study).
Takahama T; Sakai K; Takeda M; Azuma K; Hida T; Hirabayashi M; Oguri T; Tanaka H; Ebi N; Sawa T; Bessho A; Tachihara M; Akamatsu H; Bandoh S; Himeji D; Ohira T; Shimokawa M; Nakanishi Y; Nakagawa K; Nishio K
Oncotarget; 2016 Sep; 7(36):58492-58499. PubMed ID: 27542267
[TBL] [Abstract][Full Text] [Related]
57. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.
Kim HJ; Lee KY; Kim YC; Kim KS; Lee SY; Jang TW; Lee MK; Shin KC; Lee GH; Lee JC; Lee JE; Kim SY
Lung Cancer; 2012 Mar; 75(3):321-5. PubMed ID: 21930325
[TBL] [Abstract][Full Text] [Related]
58. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
Sands J; Li Q; Hornberger J
Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
[TBL] [Abstract][Full Text] [Related]
59. Plasma EGFR mutation testing in non-small cell lung cancer: A value proposition.
Oellerich M; Christenson RH; Beck J; Walson PD
Clin Chim Acta; 2019 Aug; 495():481-486. PubMed ID: 31125533
[TBL] [Abstract][Full Text] [Related]
60. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
